45 listed sites: China (45) - 09 May `25ICP-332 tablets for nonsegmental vitiligo

ICP-332 tablets for nonsegmental vitiligo

Official title: A Phase II/III Randomized, Double-blind, Placebo-controlled, Parallel Group, Adaptive Design, Multi-center Study to Evaluate the Efficacy and Safety of ICP-332 in Subjects With Non-segmental Vitiligo

Status: Recruiting now

Description:

Beijing InnoCare Pharma Tech Co., Ltd. plans to enroll about 603 participants. The study drug is an experimental oral or topical immune-modulating medicine designed to reduce inflammatory signaling. Researchers hope it will slow melanocyte damage and help skin regain color. Possible effects may include headache, stomach upset, skin irritation, and infections; the full safety profile is still being studied. People ages 12 to 75 may qualify. The study is recruiting at 45 listed sites in China.

Start date: May 09, 2025

Completion date: April 01, 2029

Organizer: Beijing InnoCare Pharma Tech Co., Ltd.

Contact: Flora Xiang, Doctor

Tel.: 021-52887775

Email: flora_xiang@vip.163.com

Link: https://clinicaltrials.gov/study/NCT07047612

Clinical Trial Alerts

Sign up and be the first to know about updates on this trial.

This request will be sent with the trial reference ICP-332 tablets for nonsegmental vitiligo . By submitting you agree to our Privacy Policy.

FAQOther Questions

  • Белые пятна на теле? Витилиго?

    Гид по Витилиго — ваш компас в лабиринте загадочной болезни и непростых решений. Здесь всё по-честному, по делу и на понятном языке. Вы найдёте здесь: Объяснения, что происходи...

  • What are risks of oral and topical corticosteroids?

    Corticosteroid drugs (like hydrocortisone, and others) are often used for treating vitiligo. By mimicing the effects of hormones your body produces naturally in your adrenal gla...

  • Does vitiligo increase the risk of skin cancer?

    No, it does not. Despite common misconceptions, people with vitiligo are actually at a lower risk of developing skin cancer—including both nonmelanoma skin cancer (NMSC) and mal...